AstraZeneca Plc Guides 2017 Rev to be broadly in line with 2013
- Continues to believe a return to growth should come earlier than analyst consensus currently forecasts.
- Has initiated trials for its cancer immunotherapy combination portfolio for which first data readouts are anticipated in 2014/2015.
- Has initiated trials for its cancer immunotherapy combination portfolio for which first data readouts are anticipated in 2014/2015.